Victor M. Rivera - Concepedia

Author

Victor M. Rivera

Ariadne Diagnostics (United States)ORCID

Also Known As

Rivera, V.M., Rivera, Victor, Ruslan Mustafin, V M Rivera, V Rivera, V. M. Rivera, V. Rivera, V.M. Rivera, V.M.Vázquez Rivera, VICTOR M. RIVERA

287

Publications

15.6K

Citations

H-Index

176

Concepts

All Affiliations

Ariadne Diagnostics (United States)The University of Texas MD Anderson Cancer Center University of Michigan University of California, San Francisco Michigan Center for Translational Pathology

About

Victor M. Rivera is an author at Ariadne Diagnostics (United States) specializing in medicine, cell biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	76	7.6K
2	Health Sciences	18	20	1.3K
3	Natural Sciences	14	14	1.7K
4	Engineering	4	4	112
5	Social Sciences	1	1	27

Victor M. Rivera

128

Publications

15K

Citations

H-Index

Page 1

	Year	Citations
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu, Cancer Cell Hematological MalignancyTumor BiologyChronic Myeloid LeukemiaOncologyPan-bcr-abl Inhibitor	2009	1.2K
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, New England Journal of Medicine	2013	1.1K
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah, New England Journal of Medicine	2012	759
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Blood	2018	572
A humanized system for pharmacologic control of gene expression Victor M. Rivera, Tim Clackson, Sridaran Natesan, Nature Medicine Systems BiologyMedicinePharmacogenomicsAntisense TherapyGene Expression	1996	541
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK Ryohei Katayama, Tahsin M. Khan, Cyril H. Benes, Proceedings of the National Academy of Sciences	2011	538
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase Wei‐Sheng Huang, Shuangying Liu, Dong Zou, Journal of Medicinal Chemistry Drug TargetAnaplastic Lymphoma KinaseTumor BiologyMedicinal ChemistrySelective Alk Inhibitors	2016	392
Discovery of 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant Wei‐Sheng Huang, Chester A. Metcalf, Raji Sundaramoorthi, Journal of Medicinal Chemistry Drug TargetImmunologyMolecular BiologyT315i Gatekeeper MutantNative Bcr-abl	2010	357
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial Scott Gettinger, Lyudmila Bazhenova, Corey J. Langer, The Lancet Oncology Other MalignanciesMedicinePharmacologyPathologyBronchial Neoplasm	2016	348
Regulation of Protein Secretion Through Controlled Aggregation in the Endoplasmic Reticulum Victor M. Rivera, Xiurong Wang, Scott Wardwell, Science Protein SecretionTransient SecretionGene DeliveryBiomedical EngineeringInsulin Signaling	2000	342

Page 1